PMCB News and Press, PharmaCyte Biotech Inc. From 10/07/22

PharmaCyte Biotech ( NASDAQ: PMCB ), a biotech focused on cellular therapies, announced Friday that the company’s board has tasked its Business Review Committee with evaluating business opportunities to generate optimum value for shareholders. In addition, PMCB anno...

LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box for potential development of cellula...

PharmaCyte Biotech ( NASDAQ: PMCB ) said on Monday that it had signed a cooperation agreement with Iroquois Master Fund and its affiliates to includes two of Iroquois’ director designees to its Board of Directors. ( PMCB ) rose ~4% be...

- 7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders - Circumvents Proper Vetting of Directors; Proposes Slate with Multiple Connections and Allegiances to Iroquois with History of Value Destruction - Proposes 15-Person Boar...

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc. PR Newswire Reiterates its Belief that the Root Cause of the Company's Problems is an Insular and Dysfunctional Board Comprised of Chairman and CEO Kenneth W...

PharmaCyte Biotech ( NASDAQ: PMCB ) said it had begun the pilot phase of its two-phase pig study of CypCaps to treat pancreatic cancer. ( PMCB ) stock up ~4% before the bell. The U.S. Food and Drug Administration has requested data from a large animal,...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has commenced the pilot phase ...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has achieved positive interim ...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced its preliminary unaudited financial...

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS PR Newswire NEW YORK , July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Fri...